Respiree offers a plug and play, non-invasive cardio-respiratory sensor that marries the use of remote breath-cardio sensors and artificial intelligence for targeted cardio-respiratory diseases predictions and diagnosis.

It is currently used by hospitals treating patients with cardio-respiratory diseases aged between 65 and 85. The patented hardware technology replaces manual charting for nurses, enables seamless transition from hospital-to-home care and alerts patients who are deteriorating or at risk of deterioration up to 24 hours in advance.

Several clinical validations have been conducted and the Cardio-Respiratory Monitor is an HSA Approved Class B Medical Device, awaiting FDA 510(k) approval. Its latest use case includes detecting symptoms of Covid-19. Respiree has been engaging Singapore hospital groups in direct sales and is planning to expand into the Thailand, Vietnam, and US markets by leveraging on various channels like pharmaceutical companies and telemedicine companies.

Respiree was founded by Dr Gurpreet Singh, Dr Chris Ho, Dr Patrick Cozzone and Dr Malini Olivo in 2019, a spin-off from the Agency for Science, Technology and Research (A*STAR) of Singapore. The company is supported by A*STAR, Accelerate Technologies and Enterprise Singapore.